The presence of CD8+ TILs, the expression of tumour immunogenic neoantigens and PD-L1/PD-1 positivity are characteristic of the high-MSI/MMR-d phenotype, identifying patients who could benefit from immunotherapy [22]. The gene discussed is CD274; the disease is neoplasm.